{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T02:17:51Z","timestamp":1648952271637},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6470","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T18:10:24Z","timestamp":1476468624000},"page":"3025-3028","source":"Crossref","is-referenced-by-count":0,"title":["The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma"],"prefix":"10.2169","volume":"55","author":[{"given":"Shigeo","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuroha","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621-4629, 2010.","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sonneveld P, Goldschmidt H, Rosi\u00f1ol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31: 279-287, 2013.","DOI":"10.1200\/JCO.2012.48.4626"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Nooka AK, Kaufman JL, Behera M, et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer 119: 4119-4128, 2013.","DOI":"10.1002\/cncr.28325"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32: 587-600, 2014.","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29: 587-590, 2005.","DOI":"10.1016\/j.leukres.2004.11.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ludwig H, Sonneveld P, Davies F, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist 19: 829-844, 2014.","DOI":"10.1634\/theoncologist.2014-0042"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120: 9-19, 2012.","DOI":"10.1182\/blood-2012-02-408898"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22: 1419-1427, 2008.","DOI":"10.1038\/leu.2008.99"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Glasmacher A, von Lilienfeld-Toal M. The current status of thalidomide in the management of multiple myeloma. Acta Haematol 114 (Suppl 1): 3-7, 2005.","DOI":"10.1159\/000087037"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.","DOI":"10.1056\/NEJMra1011442"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32: 634-640, 2014.","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118: 4519-4526, 2011.","DOI":"10.1182\/blood-2011-06-358812"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/20\/55_55.6470\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:11:28Z","timestamp":1498338688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/20\/55_55.6470\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":12,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6470","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}